Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 7/20 | 0.92 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | MMP1 | P03956 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236658 | 1.00 | POLH (0.92) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL20630781 | 1.00 | POLH (0.92) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL31236655 | 1.00 | POLH (0.92) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL25262255 | 0.96 | POLH (1.00) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL17620378 | 0.92 | POLH (0.89) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL23442033 | 0.89 | POLH (0.78) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL30326405 | 0.89 | POLH (0.78) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL29139772 | 0.89 | POLH (0.78) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL25304942 | 0.88 | POLH (1.00) | POLHALOX5KDM4EMEN1MMP1 | |
| SCHEMBL30663836 | 0.88 | POLH (1.00) | POLHALOX5KDM4EMEN1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323814-A1 | MEDICAL COMPOUND | VERA SALUS RICERCA S.R.L. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-20200323814-A1 | MEDICAL COMPOUND | VERA SALUS RICERCA S.R.L. (IT) | 2020-10-15 | — | — | US | disclosed |
| CN-110831589-A | Medical compounds | 维拉萨卢斯里切尔卡有限公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2019008537-A9 | MEDICAL COMPOUNDS | VERA SALUS RICERCA S.R.L. (IT) | 2020-02-20 | — | — | WO | disclosed |
| WO-2019008537-A1 | MEDICAL COMPOUNDS | VERA SALUS RICERCA S.R.L. (IT) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323814-A1 | MEDICAL COMPOUND | MTNR1B, CBR1, MTNR1A | POLH 3942/4885ALOX5 730/4885KDM4E 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.